Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027) (NCT01106287), a randomized phase 1 study. The primary outcome is Number of Participants Who Experienced One or More Adverse Events During the Study.

2. Clinical Question

This is a safety and tolerability question, not an estimate of clinical benefit. The listed outcome records whether participants experienced adverse events; it does not, by itself, describe each event’s severity, timing, cause, duration, or clinical importance. The registry’s summary identifies clinical and laboratory adverse experiences as the basis for evaluating safety and tolerability, but further details about event collection and assessment are not reported in the registry record.

The multi-period sequences include different combinations of active doses and placebo. The registry does not describe how sequence assignment was generated, how participants were allocated among sequences, or how the period-by-period data were analysed. Those details matter when interpreting counts collected across repeated periods, because a count for an individual dose is not necessarily a comparison of independent groups. The available record supports a descriptive reading of the posted counts, rather than a conclusion about differences between doses or placebo.

3. Trial Design

This was a randomized, double-masked Phase 1 study with a registry-reported parallel model. The study enrolled 13 participants with type 2 diabetes and is recorded as completed. Its stated purpose was to evaluate the safety and tolerability of single doses of MK-0941 using clinical and laboratory adverse experiences.

The registry lists four treatment sequences, each covering five periods. Across those sequences, participants could receive MK-0941 at 60 mg, 80 mg, 100 mg, 120 mg, or 140 mg, as well as placebo. The order differs across the listed sequences. For example, the registry lists placebo in different periods and places active doses in different positions. The sequence descriptions establish that several periods and treatments were part of the scheduled regimen, but they do not explain the timing between periods or how results were attributed to a specific exposure.

The registry’s model classification is parallel, while the sequence descriptions show multiple treatment periods. The relationship between that classification and the period-by-period schedule is not explained in the registry record. It is therefore safest to report both as recorded without assuming a particular crossover analysis or interpreting each dose group as an independent parallel arm.

The study started in 2009-10, reached primary completion in 2010-01, and has completed status. The primary outcome timeframe is up to 30 days after the last dose of study drug. The stated primary outcome is the number of participants who experienced one or more adverse events during the study. The registry lists 13 enrolled participants, while the number at risk varies among the reported dose groups. It does not describe the reasons for those varying denominators or give a participant flow account.

Details of the planned statistical methods, sequence allocation, masking procedures, dose administration schedule, eligibility criteria, and handling of period effects are not reported in the registry record. The counts can be described as posted, but the record does not provide enough design or analysis detail to reconstruct a treatment-effect comparison.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: All participants receiving any dose of MK-0941 or placebo

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants Who Experienced One or More Adverse Events During the Study, measured over Up to 30 days after the last dose of study drug.

The primary endpoint is the number of participants who experienced one or more adverse events during the study. Its stated timeframe extends up to 30 days after the last dose of study drug, and its population is described as all participants receiving any dose of MK-0941 or placebo. In the posted results, the safety information is separated into serious adverse events and other adverse events for each listed dose and placebo.

A participant-count endpoint gives a direct summary of how many people had an event, rather than counting every event occurrence. In general, this can help avoid treating multiple events in one participant as though they came from separate participants. However, a participant-level count does not show the number of events each person experienced, the event descriptions, onset and duration, or whether an event was considered related to treatment. Those details are not reported in the registry record.

Adverse-event outcomes are used in safety evaluations because they capture undesirable experiences observed during a study. The interpretation depends on the way events are collected, classified, and attributed to treatment, as well as on the amount of observation time. The record identifies a post-dose follow-up window but does not describe the detailed collection or adjudication procedures.

The endpoint’s stated timeframe covers the study and follow-up after the last dose; the registry does not provide a separate estimate for each period or a time-to-event analysis. The posted participant counts therefore offer a descriptive view of reported safety events, not a complete account of event timing or a causal estimate of treatment effects.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

For a binary safety outcome, each participant is classified according to whether the event occurred or did not occur within the specified observation window. A simple descriptive summary gives the number of participants with the event and the number at risk. In this study, the posted results distinguish serious adverse events from other adverse events for each dose group and placebo. These counts are useful for describing the observed data, but they are not, by themselves, evidence that the groups differ beyond chance variation.

What do counts and denominators convey?

The count indicates how many participants were recorded with an event, while the denominator indicates how many participants were at risk in that group. Both are needed to interpret a count: the same count can have different meaning when the number observed differs. Here, the denominators differ between the dose groups and placebo. Because the registry does not explain the reasons for those differences, comparisons should be cautious. In general, a denominator also depends on the analysis population and the rules for determining whether a participant is at risk; those rules are not described in the registry record.

A participant count is different from an event count. One participant may have more than one adverse experience, but a participant-level endpoint counts that person once for the relevant category. The record does not provide event-level listings or explain how multiple experiences in one participant were classified. It therefore does not support conclusions about the total number of individual events, their recurrence, or their pattern over time.

Why are there no treatment-effect estimates?

A treatment-effect estimate compares outcomes across groups using a defined statistical method. Depending on the design and endpoint, an analysis might estimate a risk difference, relative measure, or model-based contrast, with uncertainty represented by a confidence interval. These are general statistical concepts; the registry does not report such estimates for this study. It also reports no p-values or adjusted analyses. No recalculated comparison is presented because the multiple-period sequences and analysis structure are not described sufficiently to define a valid unadjusted comparison from the posted counts.

Randomization can support unbiased comparisons when allocation and analysis are conducted as planned, but it does not remove uncertainty or repair missing design information. The registry identifies the study as randomized and double-masked. It does not report the randomization method, sequence allocation details, concealment procedures, or the statistical model used. Thus, those labels cannot establish how the reported dose-specific counts should be compared.

How do repeated periods affect interpretation?

The listed sequences assign treatments across five periods, and participants may therefore have observations associated with more than one treatment. In general, observations from the same participant can be correlated: a participant’s outcomes across periods may share characteristics. A method that accounts for this dependence can produce different uncertainty estimates from a method that assumes independent groups. The registry record does not identify the analysis unit, describe period effects, or state whether carryover was considered. The registry model field says parallel, so the available information does not justify labelling the analysis as a crossover analysis either.

Period, sequence, and exposure duration can matter in studies with repeated treatment periods. In general, a period effect is a difference associated with the time or order of observation, while carryover refers to an effect of an earlier treatment that persists into a later period. These concepts are relevant to interpreting a multi-period schedule, but the registry does not report whether or how they were addressed. No assumptions about washout intervals or treatment persistence can be made from the sequence descriptions alone.

What does a confidence interval add?

In general, a confidence interval pairs an estimate with a range that reflects statistical uncertainty under a specified method. Wider intervals indicate less precision, while narrower intervals indicate greater precision, subject to the model and data assumptions. A count without an interval does not show the range of plausible treatment contrasts. Since no intervals or treatment-effect estimates are reported, the precision of any difference between MK-0941 and placebo cannot be assessed from the registry results.

Small samples can make estimates imprecise, particularly when events are uncommon. This is a general statistical consideration, not a claim about a particular underlying event rate in this study. Zero serious events in the listed groups does not prove that the underlying risk is zero. The registry does not provide an interval for these zero counts, and no calculation is introduced.

What analysis details are missing?

The registry record does not report the planned statistical analysis, a sample-size justification, interim analyses, or an inferential analysis result. It does not state how missing observations were handled or whether the posted counts use an intention-to-treat, per-protocol, or safety population beyond the primary outcome description. The stated primary population is participants receiving any dose of MK-0941 or placebo, but a detailed analysis-population definition is not reported.

These omissions mean that statistical significance, comparative precision, and adjustment for repeated observations or multiple comparisons cannot be evaluated. The descriptive counts remain interpretable as registry results, but they should not be substituted for an unreported analysis plan or treated as a formal test of dose effects.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists several MK-0941 doses, placebo, multiple treatment periods, and a primary outcome described as having several categories or time points. It does not reduce that outcome to one comparison, and no inferential analyses are reported. The registry record does not state which comparisons, if any, were prespecified as primary statistical tests or how multiplicity was addressed.

Multiplicity is a general issue that arises when several hypotheses or outcomes are examined. Without a prespecified analysis strategy, repeated testing can increase the chance of finding an apparently notable result by chance. No multiplicity adjustment or hierarchy of comparisons is reported, so the posted counts should be read descriptively rather than as a series of confirmatory findings.

Missing-data methods are not reported in the registry record. The record does not explain whether any outcome observations were missing, how participants with incomplete follow-up were handled, or why the number at risk differs across the listed groups. It is not possible to infer that there were no missing observations from the posted denominators alone.

The primary outcome population is described as all participants receiving any dose of MK-0941 or placebo. Beyond that description, the registry does not define the analysis population or report whether a separate safety population was used. It also does not report an intention-to-treat analysis or a per-protocol analysis. These details affect the interpretation of participant counts, especially in a study with several treatment periods and dose exposures.

Because there are no reported analysis results, there is no basis for assessing multiplicity control, missing-data sensitivity, or consistency across analysis populations. The available evidence is limited to descriptive counts and the record’s stated outcome description.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The registry reports zero serious adverse events among participants at risk for each listed MK-0941 dose and placebo. Death counts are not reported in the registry record. A zero count means no serious adverse events were recorded in the posted results for that group; it does not establish that the underlying risk is zero or that such events could not occur in a larger population.

Serious adverse events should be distinguished from other adverse events. The registry reports other adverse events in each group: 2 among 10 participants at risk for 60 mg, 6 among 9 for 80 mg, 4 among 9 for 100 mg, 9 among 9 for 120 mg, 4 among 9 for 140 mg, and 4 among 13 for placebo. Those counts do not indicate that the events were serious. The registry does not provide the event terms, severity details for non-serious events, or assessments of relatedness.

The group denominators vary, and the schedule lists repeated treatment periods. The registry does not explain the allocation of participants to each sequence or how exposure-specific counts were derived. Therefore, these numbers are best read as the recorded safety counts, not as directly comparable estimates of risk between independent groups. No statistical comparison or uncertainty interval for serious events is reported.

12. What the Result Does, and Does Not, Mean

The results show that the registry recorded no serious adverse events in the listed dose groups or placebo group, while it recorded other adverse events in all listed groups. The counts of participants with other adverse events vary by group. These observations describe the posted safety data for this study and its participants; they are not a formal estimate of a treatment effect.

The data do not establish that MK-0941 caused or prevented any adverse event. The registry provides no inferential analysis, confidence intervals, p-values, or event-level descriptions. The number at risk varies across the groups, and the treatment schedule contains multiple periods and sequences. The record does not explain how those design features were incorporated into analysis. Without that information, a simple visual or numerical comparison across group counts cannot settle whether a difference reflects treatment, chance, or features of the study design.

Likewise, zero serious events in a small study does not demonstrate that serious events are impossible or that the absence of recorded events would persist in a larger or different population. The results do not characterize uncommon harms, long-term outcomes, or clinical benefit. The study’s stated focus is safety and tolerability after single doses, and the primary outcome window extends up to 30 days after the last dose.

The registry record does not report a sample-size justification, analysis plan, or missing-data approach. It also does not report the circumstances of individual events, treatment relatedness, or mortality counts. Those omissions limit how much can be concluded from the event counts and prevent assessment of comparative precision.

Accordingly, the sound interpretation is narrow: the posted record gives descriptive counts of serious and other adverse events across the listed exposures. It does not support a claim that one dose is safer or less safe than another, or that any dose differs from placebo. Those questions would require an analysis suited to the study’s treatment sequences and complete reporting of the methods and results.

13. Why This Trial Matters Statistically

This study illustrates why a safety table of counts is not the same as a comparative statistical analysis. The registry lists several dose levels, placebo, and multi-period treatment sequences. The counts are straightforward to read, but the structure behind them affects which comparisons are valid and how uncertainty should be quantified. Knowing that a study was randomized and double-masked is useful, yet those labels do not replace details about sequence assignment, analysis units, or the model used.

It also highlights the distinction between event categories. A report of no serious adverse events is not equivalent to a report of no adverse events: the registry separately records other adverse events in each group. Readers need to keep the category and denominator in view rather than treating a single zero as a complete safety summary.

The varying numbers at risk and the study’s repeated periods raise questions about dependence among observations and participant exposure. In general, methods that account for repeated observations can differ from independent-group methods in their uncertainty estimates. The registry record does not describe such methods, making it important not to overinterpret apparent differences in raw counts.

Finally, the record demonstrates how much statistical interpretation depends on transparent reporting. Without inferential estimates, confidence intervals, sample-size justification, missing-data procedures, or a stated multiplicity strategy, readers can describe the observed counts but cannot assess comparative precision or confirmatory evidence. Clear reporting of the analysis plan and how the period-based data were used would be needed to interpret treatment contrasts more fully.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation is the small enrollment: the registry lists 13 participants. The dose-specific numbers at risk are 10 for 60 mg and 9 for each of the other listed MK-0941 doses, while placebo has 13 at risk. These denominators are not explained in the registry record, and the record does not describe participant flow or reasons for any differences. Counts from groups with few participants provide limited information about the range of possible event patterns.

The schedule lists four treatment sequences across five periods, but the registry model is classified as parallel. The registry does not explain how these descriptions relate, how participants were assigned to sequences, or whether participants contributed to more than one dose-specific count. It also does not state how period or sequence effects, repeated observations, or possible carryover were handled. This limits interpretation of comparisons across dose groups and placebo.

There are no reported statistical analyses, confidence intervals, p-values, or treatment-effect estimates. The registry does not report the statistical plan, sample-size justification, interim analyses, missing-data methods, or multiplicity procedures. The primary outcome is described as involving several categories or time points and is not reduced to one comparison.

Safety detail is also limited. The record gives counts for serious and other adverse events but does not list event terms, event timing, duration, severity beyond the serious classification, or relatedness to study treatment. Death counts are not reported in the registry record. The stated follow-up extends up to 30 days after the last dose, so the record does not establish longer-term safety outcomes.

These limitations mean the posted counts support description of recorded events, but not a precise or definitive comparison of safety across doses or versus placebo.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027) — NCT01106287.
• Registry record last updated 2016-02-04; status last verified 2016-02.
• Results first posted 2012-12-13.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed randomized, double-masked Phase 1 study of single doses of MK-0941 in participants with type 2 diabetes. It lists 13 enrolled participants, a parallel model classification, and four treatment sequences spanning five periods. The listed exposures include MK-0941 doses of 60 mg, 80 mg, 100 mg, 120 mg, and 140 mg, as well as placebo.

The primary outcome is the number of participants experiencing one or more adverse events during the study, with a timeframe up to 30 days after the last dose. The posted results report no serious adverse events in the listed groups and report other adverse-event counts by dose and placebo. The numbers at risk vary by group.

No inferential analysis, treatment-effect estimate, confidence interval, or p-value is reported. The registry record does not explain how the multi-period sequences were analysed, how missing data were handled, or why denominators vary. The results therefore support a descriptive account of the recorded safety counts, while comparative interpretation remains limited.